← All indications
Onychomycosis
A fungal infection of the nail, usually caused by DERMATOPHYTES; YEASTS; or nondermatophyte MOLDS.
Drugs by status
Approved for this indication (7)
Phase 4 trials (5)
Phase 3 trials (2)
Phase 2 trials (21)
Phase 1 trials (3)
Other trials (5)
Organizations
Organization Involved with Phase 4 Indications (14)
Organization Involved with Phase 3 Indications (13)
Organization Involved with Phase 2 Indications (42)
- 9305-9954 Quebec Inc
- Mayne Pharma
- Merck
- Hallux, Inc.
- Hisamitsu Pharmaceutical Co., Inc.
- MacroChem Corporation
- Meiji Seika Pharma Co., Ltd.
- BlueWillow Biologics
- Nitric BioTherapeutics, Inc
- Talima Therapeutics, Inc.
- Viamet
- Virginia Clinical Research, Inc.
- photonamic GmbH & Co. KG
- MediQuest Therapeutics
- Radiant Research
- The Guenther Dermatology Research Centre
- University of Brasilia
- Taro Pharmaceuticals
- Novum Pharmaceutical Research Services
- Oregon Medical Research Center
- Klinikum Vest - Knappschaftskrankenhaus, Recklinghausen
- Minnesota Clinical Study Center
- BioStrategics Consulting Ltd
- Innovaderm
- University of Gothenburg
- J&S Studies Inc.
- Oregon Dermatology and Research Center
- Lynderm Research Inc
- Dermatology Research Center, Inc
- UltraNova Skincare
- +12 more
Organization Involved with Phase 1 Indications (2)
Organization Involved with Other Experimental Indications (10)